



## **THE OHIO STATE UNIVERSITY**

WEXNER MEDICAL CENTER

### **SOP-10: Subject Screening and Recruitment**

#### **1. Objective**

To ensure that the Principal Investigator (PI) and all research team members assisting in the conduct of clinical research are informed about their obligations and responsibilities as they pertain to Good Clinical Practices (GCP), the investigational plan, applicable regulations, guidances, and institutional policies. This Standard Operating Procedure (SOP) applies to the written procedures followed by all members of a clinical research team involved in the conduct of human subjects' research at The Ohio State University Wexner Medical Center (OSUWMC), hereafter called the investigational site. These detailed instructions promote compliance in conducting clinical research.

**SOP-10** describes the process for subject screening and recruitment for clinical research. Attachment templates include:

**A: Screening Log**

**B: Subject Eligibility Criteria Checklist**

**C: Enrollment Log**

#### **2. Responsibility**

The College of Medicine Center for Clinical Research Management (COM-CCRM) develops, implements, and maintains SOPs. The need to write a new or revise an existing SOP is based upon changes to federal regulations, guidelines, institutional policies, or procedures. These documents will be provided to departments and research teams conducting human subjects' research. Departments or research teams may develop additional research SOPs or a Research Procedure Addendum (RPA) to expand on an existing SOP, however this need should be limited.

The PI is ultimately accountable for all clinical research activities and is responsible for the appropriate delegation of tasks to individuals with adequate training and education to perform such tasks. It is the responsibility of all members of the clinical research team involved in supervising, managing, or conducting study-related activities to follow the SOPs. The clinical research team may include but is not limited to the following members:

#### **Research Team Members**

Principal Investigator (PI)	Clinical Research Coordinator (CRC)
Sub-Investigator or Co-I (Sub-I or Co-I)	Clinical Research Assistant (CRA)
Clinical Research Manager (CRM)	Other Research Staff as appropriate
Clinical Research Specialist (CRS)	Administrative and Support Staff

#### **3. Definitions**

Please refer to the SOP Glossary document for detailed definitions of commonly used clinical research terminology.

## 4. Procedures

### A. Development of Screening and Recruitment Plan

Prior to opening a research study for recruitment, the delegated clinical research team member assigned to the protocol, in collaboration with the PI, will identify the target population for potential research study subjects. The Center for Clinical and Translational Science (CCTS) [Recruitment Toolkit](#) may also offer additional support for recruitment strategies.

An appropriate screening and recruitment plan will be developed prior to the IRB submission for each protocol which may include, but is not limited to, physician referral and marketing materials such as broadcasts or print advertisements.

Covered entities may use and disclose PHI to researchers to aid in study screening and recruitment. This may allow a researcher to identify potential study participants if an appropriate Partial or Full Waiver of HIPAA Authorization has been approved for the research study, there is an IRB approved recruitment protocol, or the potential research subject has provided written HIPAA Authorization.

All screening and recruitment plans will be outlined in detail in the IRB submission materials for review and approval prior to implementation. If at any time additional or alternative strategies need to be implemented, the PI in collaboration with the delegated research team members will develop these and submit to the IRB for review and approval prior to implementation.

### B. Screening Procedures

Based on the inclusion/exclusion criteria for a study, identify the target population for finding potential study subjects. Identify subjects who meet all criteria that are able to be assessed prior to informed consent.

Patient information from approved hospital sources may be used for screening for IRB-approved research protocols by OSU investigators and OSU research team members if one of the following is met:

- An appropriate Partial or Full Waiver of HIPAA Authorization has been approved for the research study
- There is an IRB approved recruitment protocol
- The potential research subject has provided written HIPAA Authorization

Approved hospital sources include clinical records controlled by Medical Information Management (MIM) and the Information Warehouse (IW).

If a screening log is not provided by the sponsor, the delegated research team member may develop a screening log based upon the study inclusion/exclusion criteria to collect pre-screening information on all potential subjects (*See Attachment A: Screening Log*). If a potential subject is not consented, or declines to enroll in a study,

but the study sponsor requires a record of individuals who were screened, that record should *not* include any identifiable information. However, if identifiable information is needed for a screening log, a waiver of HIPAA Authorization from the IRB or Privacy Board is required and all identifiers must be destroyed at study termination.

### C. Recruitment Procedures

The delegated research team members will work with the PI, Sub-Investigators, referring physicians and other clinical team members to implement an appropriate recruitment process as outlined in the examples below and ensure appropriate institutional approvals are in place.

The delegated research team members, in collaboration with the clinical team, will be responsible for discussing the details of participation in the clinical research study. Informed consent and HIPAA authorization will be obtained from the subject prior to performing study specific procedures.

#### *Recruitment: Without an Existing Patient Care Relationship*

If an investigator or research team member does not have an existing patient care relationship with a potential subject, the investigator or research team member may be permitted to access patient information of potential subjects for recruitment purposes by either of the following processes:

- Obtaining a partial waiver of individual HIPAA authorization for recruitment purposes from the IRB before accessing clinical patient information to identify or recruit potential research subjects to that specific IRB approved study.
- Through an IRB-approved recruitment protocol that describes how research team members will access the patient information of potential subjects for screening and recruitment purposes.

#### *Recruitment: Existing Patient Care Relationship*

If the investigator is a credentialed clinical care staff member and has an existing patient care relationship with a potential subject, then the investigator and members of the clinical treatment team (clinical care employees) who are under the direct supervision of the investigator may access patient information for identifying and contacting potential subjects for the protocol that has been approved by the IRB.

When possible, a member of the clinical care team that has an existing patient care relationship with the potential subject should introduce research team members who may not be members of the clinical team or clinical care employees to the patient and bridge the gap to discuss possible research study participation. This can be accomplished by in-person introduction or by sending an IRB approved joint letter regarding potential participation in the study to the individual. This can also be accomplished by an IRB approved phone script.

Investigators are responsible for the security of patient information used for research and must comply with the privacy and security requirements outlined by the following institutional policies:

- [Use of Patient Information by Hospitals and Medical Staff Policy](#)
- [OSU Institutional Data Policy](#)
- [OSUWMC Information Security Policy](#)
- [OSU Research Data Policy](#)
- [OSU Information Security Standards](#)
- [Patient Information and HIPAA Policy](#)

### D. Determining Eligibility

The delegated research team member should develop an inclusion/exclusion checklist for each clinical research study with detailed guidelines for evaluation of patient eligibility if such a form has not been provided by the sponsor (*See Attachment B: Subject Eligibility Criteria Checklist*). There must be source documentation to support all requirements for determining eligibility. The subject's medical history and all relevant research screening tests and procedures must meet inclusion criteria. If a subject meets any

Effective Date: 16-DEC-2022

exclusion criteria, the subject is not eligible for enrollment. Eligibility should be based on the current IRB approved protocol; waivers of eligibility are not good practice.

After the Informed Consent Form is signed by the subject and all screening procedures are complete, the delegated research team member will review all relevant medical records (internal and external) and relevant source documents to assess the subject's full medical history. All consented subjects will be tracked on an enrollment log. If an enrollment log is not provided by the sponsor, the delegated research team member may develop a screening log to collect relevant information on all consented subjects (*See Attachment C: Enrollment Log*).

All tests, assessments, and procedures must be done within the protocol specified timeline. If there is no timeline specified, the sponsor should provide guidelines as to what is acceptable in writing prior to enrolling any subjects.

If the subject is deemed ineligible or wishes to not proceed with enrollment, the delegated research team member will document the reason the subject was not enrolled in the research study and will update the Screening and/or Enrollment Log appropriately.

## 5. Applicable Regulations, Guidances and Policies

Regulation/ Guidance/Policy	Title
21 CFR 50	<a href="#">Protection of Human Subjects</a>
21 CFR 312	<a href="#">Investigational New Drug Application</a>
21 CFR 812	<a href="#">Investigational Device Exemptions</a>
45 CFR 46	<a href="#">Protection of Human Subjects</a>
45 CFR 160	<a href="#">HIPAA Privacy Rule</a>
45 CFR 164 Subparts A and E	<a href="#">HIPAA Privacy Rule</a>
42 CFR 50 Subpart F	<a href="#">Responsibility of Promoting Objectivity in Research (Research COI)</a>
45 CFR 94	<a href="#">Responsible Prospective Contractors</a>
OSU Office of Responsible Research Practices HRRP	<a href="#">Additional Requirements for Clinical Research: ICH GCP</a>

<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Assent and Parental Permission</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Organizational Financial Conflicts of Interest</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Documentation of the Informed Consent Process</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Emergency Use of Investigational Drugs, Biologics or Devices</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Informed Consent Process and the Elements of Informed Consent</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Organizational Financial Conflicts of Interest</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Planned Emergency Research</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Privacy and Confidentiality</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Recruiting Methods, Recruitment Materials, and Participant Compensation</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Research Involving Children</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Research Involving Data and or Biological Specimens</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Research Involving Human Subjects</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Research Involving Investigational Drugs</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Research Involving Medical Devices</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Research Involving Pregnant Women, Fetuses or Neonates</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Research Involving Prisoners</a>

<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Research Involving Radiation</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Responsibilities of Principal Investigators, Co-Investigators, and Key Personnel</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Planned Emergency Research</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Review of Research by Convened IRB</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Short Form Informed Consent</a>
<b>OSU Office of Responsible Research Practices HRPP</b>	<a href="#">Vulnerable Populations: Students, Employees, and Adults Unable to Provide Consent</a>
<b>OSU Office of Business &amp; Finance</b>	<a href="#">Petty Cash and Change Funds</a>
<b>OSU Office of Research Compliance</b>	<a href="#">Human Gene Transfer</a>
<b>OSUWMC</b>	<a href="#">Use of Patient Information by the Hospital and Medical Staff</a>
<b>OSUWMC</b>	<a href="#">Patient Information &amp; HIPAA Requirements</a>
<b>FDA Guidance for Industry</b>	<a href="#">Investigator Responsibilities- Protecting the Rights, Safety, and Welfare of Study Subjects, October 2009</a>
<b>FDA Guidance for Industry</b>	<a href="#">A Guide to Informed Consent- Information Sheet</a>
<b>FDA Guidance for Industry</b>	<a href="#">Payment to Research Subjects- Information Sheet</a>
<b>FDA Guidance for Industry</b>	<a href="#">Recruiting Study Subjects- Information Sheet</a>
<b>FDA Guidance for Industry</b>	<a href="#">Screening Tests Prior to Study Enrollment- Information Sheet</a>

---

Issued: 20-FEB-2012  
Revised: 30-JUN-2017, 10-SEP-2019, 12-SEP-2022